5 May 2010 07:00
| (AIM: SAR) | 5 May 2010 |
SAREUM HOLDINGS PLC("Sareum" or the "Company")
Sareum to Present at BIO 2010
Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce that Dr Tim Mitchell, CEO, will present Sareum's Chk1 kinase cancer research programme and SKIL technology platform ("SKIL") at the Bio Industry Organisation ("BIO") International Convention later today.
BIO, being held this year in Chicago, USA, is the largest global event for the biotechnology industry. Dr Mitchell's presentation will take place in the UK Innovation Zone, hosted by UK Trade & Investment ("UKTI").
SKIL (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora, VEGFR-3 and FLT3 cancer and auto-immune disease research programmes. SKIL has the potential to generate drug research programmes that target many other kinase types.
Sareum's Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. Novel chemical compounds developed by the collaboration have been shown to increase the effectiveness of current cancer therapeutics in in-vivo cancer models.
Sareum's CEO, Dr Tim Mitchell, commented: "This is a significant opportunity for us to showcase our drug research programmes and the technology behind them at this prestigious event. As well as presenting the latest progress in our drug programmes, it is important for us to demonstrate the potential for the SKIL technology platform to repeat this success."
| Sareum Holdings plc |
|
| Tim Mitchell | 01223 497 700 |
|
|
|
| Merchant John East Securities Limited (Nomad) | |
| Simon Clements/Bidhi Bhoma | 020 7628 2200 |
|
|
|
| Hybridan LLP (Broker) |
|
| Claire Noyce/Stephen Austin | 020 7947 4350 |
Notes for editors:
About Sareum Holdings plc
Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer.
Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR. For further information, please visit www.sareum.co.uk
Sareum (SAR)